Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q3 EPS of ($0.28), $0.05 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.07 million.

Earnings